Adjuvant high-dose-rate brachytherapy in the management of oral cavity cancers: 5 years of experience in Iran.

CONCLUSIONS: HDR-IBT as a monotherapy or in combination with EBRT is an appropriate option for the management of oral cavity squamous cell carcinomas, and supports the improvement in treatment outcomes and toxicity profiles in adjuvant settings. PMID: 28951751 [PubMed]
Source: Journal of Contemporary Brachytherapy - Category: Cancer & Oncology Tags: J Contemp Brachytherapy Source Type: research